Clinical Trial Update: Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial comparing erlotinib with temozolomide or carmustine in patients with recurrent glioblastoma multiforme has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• BiCNU (carmustine)
• Tarceva (erlotinib)
• Temodar (Temozolomide)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED